trending Market Intelligence /marketintelligence/en/news-insights/trending/hD_SvfepaGueGfH5wB_Rrw2 content esgSubNav
In This List

US FDA approves 2 Teva Pharmaceutical asthma inhalers

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


US FDA approves 2 Teva Pharmaceutical asthma inhalers

The U.S. FDA approved two Teva Pharmaceutical Industries Ltd. asthma inhalers.

The inhalers, AirDuo RespiClick and ArmonAir RespiClick, will be available for adolescent and adult patients via prescription later this year.